BPO 0.00% 0.3¢ bioprospect limited

mono - Partners - Joint venture - but a takeover no - the R&D...

  1. 6,187 Posts.
    lightbulb Created with Sketch. 497
    mono - Partners - Joint venture - but a takeover no - the R&D focus areas are too divergent and big for one entity in startup mode [and with the range of Bios that's only to continue]- in any case LK/Gunn currently holds the upper hand, unless SLA grab the ANZ held opptions 30+M then SLA will still require friendys.
 
watchlist Created with Sketch. Add BPO (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.